Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Crizotinib, sold under the brand name Xalkori among others, is an anti-cancer medication used for the treatment of non-small cell lung carcinoma (NSCLC). Crizotinib inhibits the c-Met/Hepatocyte growth factor receptor (HGFR) tyrosine kinase, which is involved in the oncogenesis of a number of other histological forms of malignant neoplasms. It also acts…
The analysis highlights Community, Culture, Applications and Research as prominent areas in the source structure around Crizotinib.
Source areas are shown by the number of related topics found in each part of the analysis. Use smaller areas too: they can reveal specialized angles and content gaps.
Smaller areas are not necessarily less important. They contain fewer connections in this analysis and can be useful for finding specialized angles or coverage gaps.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the complete topic structure, not only the most central items. Less prominent entities and concepts can reveal missing angles, specialized context and useful research gaps. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
The extracted context around Crizotinib shows recurring relationship patterns in the source. For example, Crizotinib → ALK, An Investigational Drug, Anaplastic Large Cell Lymphoma, Brentuximab Vedotin, C-Met/Hepatocyte Growth Factor Tyrosine, Cancer, Cisplatin Or Carboplatin In, Clinical, Clinical Trial Testing The, ClinicalTrials, Combination Chemotherapy, Diagnosed Stage II-IV Anaplastic, Efficacy Of Crizotinib Versus, Gene, In Patients With Advanced, Kinase Inhibitor, Large Cell Lymphoma, National Cancer Institute, NCI Drug Dictionary, NCT00585195 Another extracted example is Crizotinib → ALK, Approval, Drug Administration, EMA, EML4-ALK, European Medicines Agency, FDA, In August, In March, In October, ROS1-positive, US Food. Use these groups to spot repeated connection types before inspecting the individual relationships.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
kinase alk lymphoma lung cell treatment non-small anaplastic cancer malignant patients gene number tumors fusion nsclc growth also refractory factor
TTTA extracted 115 structured relationships around Crizotinib. Examples in this analysis include Crizotinib → 3D model (JSmol) → Interactive image and Crizotinib → AHFS/Drugs.com → Monograph. The table shows each extracted connection, where it came from and its confidence.
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Crizotinib | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Crizotinib | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Crizotinib | ATC code | L01ED01 (WHO) | 1.00 | infobox |
| Crizotinib | Bioavailability | 43% | 1.00 | infobox |
| Crizotinib | CAS Number | 877399-52-5 N | 1.00 | infobox |
| Crizotinib | ChEBI | CHEBI:64310 N | 1.00 | infobox |
| Crizotinib | ChEMBL | ChEMBL601719 Y | 1.00 | infobox |
| Crizotinib | ChemSpider | 9801307 Y | 1.00 | infobox |
| Crizotinib | CompTox Dashboard (EPA) | DTXSID701009329 | 1.00 | infobox |
| Crizotinib | DrugBank | DB08700 Y | 1.00 | infobox |
| Crizotinib | ECHA InfoCard | 100.166.440 | 1.00 | infobox |
| Crizotinib | Elimination half-life | 42 hours | 1.00 | infobox |
| Crizotinib | Excretion | Faeces (63%), urine (22%) | 1.00 | infobox |
| Crizotinib | Formula | C21H22Cl2FN5O | 1.00 | infobox |
| Crizotinib | IUPHAR/BPS | 4903 | 1.00 | infobox |
| Crizotinib | KEGG | D09731 N | 1.00 | infobox |
| Crizotinib | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Crizotinib | Legal status | CA: ℞-only | 1.00 | infobox |
| Crizotinib | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Crizotinib | Legal status | US: ℞-only | 1.00 | infobox |
| Crizotinib | Legal status | EU: Rx-only | 1.00 | infobox |
| Crizotinib | License data | US DailyMed: Crizotinib | 1.00 | infobox |
| Crizotinib | MedlinePlus | a612018 | 1.00 | infobox |
| Crizotinib | Metabolism | Liver (CYP3A4/CYP3A5-mediated) | 1.00 | infobox |
| Crizotinib | Molar mass | 450.34 g·mol−1 | 1.00 | infobox |
| Crizotinib | Other names | PF-02341066 1066 | 1.00 | infobox |
| Crizotinib | PDB ligand | VGH (PDBe, RCSB PDB) | 1.00 | infobox |
| Crizotinib | Pregnancy category | AU: D | 1.00 | infobox |
| Crizotinib | Protein binding | 91% | 1.00 | infobox |
| Crizotinib | PubChem CID | 11626560 | 1.00 | infobox |
The concept neighborhoods around Crizotinib bring nearby vocabulary together. In this analysis, examples include Cell, Lung and Non-small. Use the clusters to find adjacent concepts and terminology that may deserve separate research.
For Crizotinib, one of the stronger structural bridges in this analysis connects Crizotinib with Mechanism of action. Bridges highlight paths between different parts of the map and can reveal research angles that are easy to miss in a flat list.
TTTA analyzes the structure around Crizotinib to surface related topics, entities, relationships, concept neighborhoods and bridge connections. Use the map to explore areas such as Community, Culture, Applications & Research, including less central topics that may reveal useful research gaps. Automatically extracted connections are research leads rather than rewritten encyclopedia content.
Source: Wikipedia — Crizotinib · EN edition · Analysis: TopicsToTalkAbout